Skip to Content
Merck
All Photos(1)

Documents

Y0000853

Fluvoxamine for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Fluvoxamine maleate, (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone-O-(2-aminoethyl)oxime maleate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C15H21F3N2O2 · C4H4O4
CAS Number:
Molecular Weight:
434.41
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fluvoxamine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

COCCCC/C(C1=CC=C(C(F)(F)F)C=C1)=N\OCCN.OC(/C=C\C(O)=O)=O

InChI

1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-

InChI key

LFMYNZPAVPMEGP-PIDGMYBPSA-N

Gene Information

human ... SLC6A4(6532)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluvoxamine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Donatella Marazziti et al.
Human psychopharmacology, 27(4), 397-402 (2012-07-19)
In this study, we explored the possible relationships between plasma fluvoxamine levels and clinical features and/or response in adult obsessive-compulsive disorder (OCD) patients treated with this drug for 6 months. Twenty OCD outpatients of both sexes who were already taking
Anton J L M van Balkom et al.
Psychotherapy and psychosomatics, 81(6), 366-374 (2012-09-12)
To compare the effectiveness of second-step treatment with cognitive therapy (CT) versus fluvoxamine in patients with obsessive-compulsive disorder (OCD) who are nonresponsive to exposure in vivo with response prevention (ERP). A 12-week randomized controlled trial at an outpatient clinic in
Tomihisa Niitsu et al.
Journal of clinical psychopharmacology, 32(5), 593-601 (2012-08-29)
Cognitive impairments in schizophrenia are associated with suboptimal psychosocial performance. Several lines of evidence have suggested that endoplasmic reticulum protein sigma-1 receptors were involved in cognitive impairments in patients with schizophrenia and that the sigma-1 receptor agonist fluvoxamine was effective
Md Shenuarin Bhuiyan et al.
Journal of pharmacological sciences, 121(3), 177-184 (2013-02-23)
Depression is associated with a substantial increase in the risk of developing heart failure and is independently associated with increased cardiovascular morbidity and mortality. Inversely, cardiovascular disease can lead to severe depression. Thus, therapy with selective serotonin reuptake inhibitors (SSRIs)
Shohei Matsunami et al.
Behavioural brain research, 233(2), 577-586 (2012-06-12)
Behavioural effects of fluvoxamine (FLV, selective serotonin reuptake inhibitor) were examined in 1-2 week old domestic chicks. Chicks were tested in an I-shaped maze equipped with a feeder (ON feeder) that served 1 or 2 grains of millet at gradually

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service